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caused by the bounded scale. Various analytical approaches have recently been
proposed for use in cross-sectional studies, however, less attention is paid to lon-
gitudinal designs. We examined the use of beta regression models to analyze HRQL
data over time using two empirical examples. METHODS: The HRQL measures
employed in our empirical examples were the generic SF-6D and the disease-spe-
cific Stroke Impact Scale (SIS). Data came from the German KORA cohort study and
from a clinical setting, respectively. We fitted mixed and marginal beta models and
explain the conceptual difference between these two model classes, namely the
population-averaged and the subject-specific perspective. We compared overall fit
and predictive accuracy of the models to the commonly used linear mixed model
(LMM). RESULTS: The SF-6D data were highly skewed to the left and the SIS data
exhibited a pronounced ceiling effect. In both examples, the beta distribution fitted
the data better than the normal distribution. Beta regression accounted for the fact
that predicted values must fall into the bounded support of the scales and overall
fit measures suggested that the mixed beta model was superior to the LMM (AIC:
2723 vs.2441 and904.1 vs.376.4). However, mixed beta regression underes-
timated the mean at the upper part of the distribution. Adjusted group mean scores
from the marginal beta model were nearly identical to those derived from the LMM.
CONCLUSIONS: Longitudinal beta regression models are potential candidates to
analyze HRQL over time since they account for the specific characteristics such
data typically have. However, our results show that in practice, estimates may only
differ slightly from those of commonly used methods.
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OBJECTIVES: The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is
one of the most used specific instruments for measuring quality of life in patients
with heart failure. It comprises 21 items conforming a total score, as well as two
domains: the physical and the emotional. The aim of this study was to evaluate the
reliability, validity, and responsiveness of the Spanish MLHFQ.METHODS: Patients
completed the MLHFQ and the SF-12 during their hospitalization for heart failure
(n1175), and 6 months after discharge (n473). Reliability was assessed by Cron-
bach’s alpha coefficient. Confirmatory factor analysis (CFA) for categorical vari-
ables was used to study construct validity. Convergent validity was assessed by
correlations between MLHFQ and SF-12 scales. To study known-groups validity,
MLHFQ at 6 months were compared according to readmission. Responsiveness was
evaluated by effect sizes and according to patients classified as improved, equal, or
worsened than at baseline. RESULTS: Cronbach’s alpha was 0.80 for the three
domains. CFA confirmed the two factor model, with factor loadings ranging from
0.56 to 0.87. Both Tucker-Lewis and Comparative Fit indexes were 0.90, but the
root mean squared error of approximation was 0.08. The highest correlations
were obtained between MLHFQ and SF-12 physical domains (r0.55), and be-
tween the emotional MLHFQ and mental SF-12 domain (r0.53), supporting the
convergent validity. Known-groups validity was shown with significantly worse
scores within patients with readmission (P0.0001). Responsiveness parameters
among improved patients were 1.20 and 1.05 for physical and total score, respec-
tively, indicating large changes, and 0.59 for emotional domain, indicating moder-
ate changes. CONCLUSIONS: The Spanish MLHFQ is valid, reliable and responsive-
ness 6 months after discharge for patients hospitalized with heart failure. Because
its simplicity and ease of application, it may be useful in routine practice and
clinical research. Further, its cross-cultural characteristics make it very useful for
comparisons among countries.
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OBJECTIVES: To propose a single score for quality of life (QoL) derived from the
SF-36 and the HAQ in patients with APS in a tertiary care center. METHODS: It is a
cohort study. Sample was stratified in two groups according to the numbers of
changes in the warfarin dosage over a period of 12 months: Group 1 ( 6 changes in
12 months) and Group 2 ( 6 changes in 12 months). This change was due to INR
oscillation. To assess quality of life, SF-36 and HAQ instruments at baseline and
after 12 months of follow-up were used. To derive the single score, a descriptive
analysis evaluated the variables. Principal component analysis (PCA) was done to
reveal the internal data structure that explains the data variance. APS score was
calculated by the sum of the values obtained by weighting the factor scores for each
component by the proportion of variability explained by the respective component.
To measure APS score consistency to patient’s preference, we based on the hypoth-
esis that Group 2 had a worse quality of life. To test it, we evaluated APS score into
the two time points. To corroborate these results, we applied repeated measures
ANOVA technique. For all statistical tests, the significance level used was  5%.
RESULTS: Group 1: 37 and Group 2: 17 individuals. The descriptive analysis indi-
cates that Group 1 has superior QoL than Group 2. After this step, the minimum and
maximum APS score was obtained: From  2.86905 to  2.797845. Higher score
means the higher the QoL. In order to corroborate our hypothesis, repeated measures
ANOVA results verified that there are significant differences between the two
groups [F (14.27) 24.13, p0.0004]. CONCLUSIONS: APS score is a valid instrument
to measure QoL in APS patients.
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OBJECTIVES: To administer a questionnaire to 14,000 women in order to measure
various aspects of women’s lifestyle, including sensitive habits, and health.
METHODS: A first population-based mailing was sent to around 31,000 women,
inviting them to complete a questionnaire on a dedicated website or on paper.
Women who did not initially respond were reminded to complete the question-
naire first through an additional mailing and then, for the ones who had still not
responded, through telephone calls. During the second reminder, they were also
offered the possibility to complete the questionnaire over the telephone. Each
reminder was performed after a 3-week waiting period. RESULTS: Among the
30,917 women contacted, 26.0% completed initially the questionnaire. After the
first reminder, the questionnaire was completed by 18.6% of the women who did
not respond to the first mailing and, after the second reminder, by 24.2% of the
women who did not respond after the first reminder. The first mailing followed by
the two reminders resulted in a 52.4% completion rate of the questionnaires. Ques-
tionnaires received after the first mailing, then after the first and second reminder
accounted for respectively 49.6%, 26.9% and 23.4% of the total amount of completed
questionnaires. When offered the possibility to complete the questionnaire on
paper or on a dedicated website, only 18.8% of the women choose the on-line
method. During the telephone call of the second reminder, when offered the pos-
sibility, most women agreed to complete the questionnaire over the telephone
(53.7%). CONCLUSIONS: The methodology employed resulted in an overall good
completion rate (52.4%). The objective of 14,000 completed questionnaires would
have not been achieved without proactive and direct to subject contacts using
reminders, including telephone contacts, allowing finally a two-fold increase of the
initial responders rate.
RESEARCH ON METHODS - Statistical Methods
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OBJECTIVES: Estimates of real-world cost-effectiveness are mostly based on obser-
vational data with non-random treatment assignments. Several methods exist to
address the resulting confounding-by-indication, including regression and meth-
ods based on propensity scores (PS). This study examined the performance of these
methods in the context of cost-effectiveness analysis. The PS-methods were: PS
matching (kernel and one-to-one), covariate adjustment using PS, inverse proba-
bility-of-treatment weighting (IPTW) and double robustness, each with several
specifications.METHODS: Thirty-eight adjustment approaches were compared us-
ing Monte Carlo simulations. In each simulation, four differently confounded sam-
ples (n2000) were drawn from a synthesized population. Incremental survival
time and costs were calculated using the results of Weibull survival and general-
ized linear regression. These regressions – with treatment as sole covariate or fully
specified with all confounders - were performed directly or after applying a PS-
method. Each approach was assessed on bias (systematic deviation from the true
effect), accuracy (proportion of simulated results within acceptable distance from
the true values) and reliability (width of bootstrapped confidence intervals) of es-
timates of incremental effects, costs and cost-effectiveness ratios. RESULTS: In
estimates of the average treatment effect in the treated (ATT), kernel and 1-to-1 PS
matching had similar bias and accuracy results, but the reliability of kernel was
better. Regarding average treatment effects for the sample as a whole (ATE), double
robustness and IPTW had the least bias and the best accuracy and reliability. Com-
bining PS methods with fully specified regression models was most likely to lead to
good results. PS covariate adjustment and regression without a PS method scored
worst. CONCLUSIONS: PS methods are preferable to conventional regression for
use in observational cost-effectiveness studies. Combining a PS method with fully
specified regression should be considered for the analysis. Since no method is
always superior, it is advised that sensitivity analyses with different techniques be
performed.
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SAME GROUP IN LONGITUDINAL OBSERVATIONAL RESEARCH: A CYSTIC
FIBROSIS EXAMPLE
Pasta DJ, Millar SJ
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OBJECTIVES: In longitudinal observational studies, patients can meet eligibility
criteria for more than one group and can be eligible multiple times for the same
group. We used Epidemiologic Study of Cystic Fibrosis data to explore different
inclusion decisions when evaluating dornase alfa treatment. METHODS: The dor-
nase alfa group included patients enrolled 2 years before starting consistent dor-
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nase alfa therapy. A lung function test (“index”) separated a 2-year pre-index pe-
riod from a 2-year post-index period for which intercepts and slopes were
independently estimated. The comparator group included patients not yet re-
ported to have received dornase alfa; their index lung function test was associated
with their eighth or subsequent even-numbered birthday. Comparator patients
could contribute more than one set of pre- and post-index periods and could also
subsequently be included in the dornase alfa group. To account for the repeated
use of patients, variance components were estimated at the patient level as well as
the case level. Different subsets of the comparator cases were analyzed. RESULTS:
There were 2230 dornase alfa patients; the comparator group included 5970 cases
from 3517 patients. The estimated difference in change in slope was 0.73.31
(P0.020). Subsetting comparators to 4985 cases from 2836 patients not also in the
dornase alfa group gave 0.610.32 (P0.058); including each of those patients only
the last time eligible gave 0.680.36 (P0.059). Subsetting to 3662 cases from 2030
patients never on dornase alfa gave 0.320.34 (P0.35). Patient-level variance com-
ponents corresponding to difference in slope and difference in intercept were near
zero and so were dropped. CONCLUSIONS: In longitudinal observational studies,
patients should be included in each group for which they meet eligibility criteria,
possibly multiple times (with appropriate covariance structures). This avoids bias
from using future information to decide whether to include a patient and loss of
power from limiting cases unnecessarily.
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Numerous assumptions and techniques are necessary to perform meta-analysis.
Some overall structural guidelines and best practices on meta-analysis exist. How-
ever, few papers compare meta-analysis techniques in application. OBJECTIVES:
To review primary meta-analysis methods and their assumptions. After method-
ology review, we applied various meta-analysis techniques to the data of various
Bacille Calmette Guerin (BCG) vaccine studies and compared the results.
METHODS: Of the currently available meta-analysis techniques, the most basic
technique was applied first. Fixed effect models assume treatment effect homoge-
neity across studies. Then, random effect models and meta-regression were ex-
plored. Each technique explicitly models treatment heterogeneity. Lastly, the pos-
sibility of publication bias was tested through the use of a funnel plot. RESULTS:
Treatment effect estimates differed depending on the meta-technique applied.
When a fixed effect model was applied to estimate vaccination effectiveness
against tuberculosis, the log odds ratio was0.436 (confidence interval [CI]:0.528,
0.344). After testing for heterogeneity and fitting a random effects model, the
estimate was reduced to 0.741 (CI: 1.120, 0.352), and the CI became wider.
When covariates were added to the model to explain the heterogeneity, the effect
of treatment was reduced even further. CONCLUSIONS: Meta-analysis results are
sensitive to the selected studies and the methodology applied. Ensuring that
proper techniques are used is critical to estimate an unbiased outcome.
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OBJECTIVES: The ISPOR Task force (TF) on Good Research Practices for RCT-CEA
aims to foster improvements in the conduct of trial-based economic analysis. The
TF recognizes the sample size of randomized clinical trials (RCT) as one of the
challenges for trial-based economic analysis, as it is typically based on the primary
clinical outcomes only. In the case of vitreomacular traction (VMT), using RCT
individual patient-level data (IPD) to establish model starting distributions within
visual acuity (VA) health-states magnifies this challenge due to the small patient
numbers within each relevant VA health-state. Our objective was to develop an
innovative approach to robustly estimate patient within-category VA health-state
starting distributions.METHODS:A baseline VA-adjusted ordered logit model used
RCT IPD to predict a patient’s VA starting distribution as a function of treatment
allocation, macular hole, vitreomacular adhesion and previous vitrectomy status.
The observed ordinal variable consisted of 6 response categories i.e. VA state as a
function of an unmeasured, continuous, latent variable Y whose values determine
the patient’s VA-state dependent specific VA thresholds. RESULTS: Treatment al-
location was not a significant predictor for within-category VA health-state start-
ing distributions (at the 5% significance level), while MH, VMA and previous vitrec-
tomy status were significant and retained in the final model. The proportional odds
assumption was tested using a likelihood ratio test and confirmed that the rela-
tionship between each pair of VA health-states was the same (chi2  0.0906).
CONCLUSIONS: In eye-disorders like VMT, estimating within-category VA health-
state starting distributions requires a different approach due to the small number
of IPD in each VA health-state. Using an ordered logit model allows a more accurate
and robust estimation of within-category VA health-state starting distributions.
Macular hole, VMA and previous vitrectomy status were significant predictors of a
patient’s within-category VA health-state starting distribution, while treatment
allocation was not.
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OBJECTIVES: With the lack of alternative strategies for calculating the dose of
cytotoxic drugs in chemotherapy regimens, body surface area (BSA), despite well-
documented limitations, remains the most frequently used measure for dosing
guidelines. This is based on the assumption that physiological variables related to
drug metabolism and elimination, such as basal metabolic rate, renal and hepatic
function, vary between individuals according to BSA. BSA has traditionally been
calculated using a formula derived from Du Bois and Du Bois and published in 1916.
It is recognised this is probably not the most accurate method of calculating che-
motherapy doses, since the formula was derived from metabolic studies using a
small number of subjects. The practice of calculating chemotherapy dose adjusted
to BSA has drawn attention due to its lack of clear scientific basis, and lack of
applicability to different genders, disease states, and culture.METHODS:A system-
atic literature review was conducted using CRD methodology to establish the av-
erage BSA in cancer patients in Europe and the variability between genders, tumour
types, and cultures. RESULTS: Meta-analysis of the findings showed significant
differences between genders overall (females 1.72m2 vs males 1.88m2), between
different tumour types (range 1.68m2 to 1.93m2) and between different European
countries (range 1.74m2 to 1.83m2). However, statistical modelling showed that a
BSA of 1.80m2 approximated the population mean and identified the dispersion to
be 1.72-1.87m2 and was therefore a valid approximation for the majority of cancer
patients in Europe. CONCLUSIONS: Establishing a patient’s BSA is important in
determining the appropriate dosage regimen, but the population norm serves as a
useful basis for drugs administered in a fixed dose formulation.
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OBJECTIVES: In the context of today’s highly globalized environment, the interest
in the transferability of data of cost evaluation in health care has strongly intensi-
fied. A methodology is proposed to explore similarity versus dissimilarity of cost
evaluation data in adult sarcoma and hence their transferability across locations
(France and Italy). METHODS: Main steps are (i) definition of the objects (e.g. coun-
tries), identification of potential variability factors, selection of final variability fac-
tors, and construction of variability areas (e.g. unit cost of personnel); (ii) measure
of distances between the objects, determination of clusters and construction of a
hierarchical tree using the cluster analysis (CA); (iii) projection of the objects into
factorial planes and linkage between objects and areas of variability using principal
component analysis (PCA). Suggested methods are applied to an international cost
evaluation performed within the European network of excellence CONnectiveTIs-
suesCAncersNETwork (CONTICANET). RESULTS: Twelve objects and 16 areas of
variability were defined. CA shows four clusters meaning that data belonging to
different clusters are dissimilar (i) chemotherapy in France, (ii) follow-up with
relapse in Italy, (iii) diagnosis, surgery, chemotherapy, radiotherapy, and follow-up
without relapse in Italy, (iv) diagnosis, surgery, radiotherapy, follow-up without
relapse, and follow-up with relapse in France. PCA opposes (i) follow-up with re-
lapse in Italy to diagnosis, radiotherapy, and follow-up with relapse in France; (ii)
chemotherapy in France to follow-up without relapse in France. In sarcoma pa-
tients, transferability is then limited for chemotherapy during the initial treatment
in France and the follow-up with relapse in Italy. Diagnosis cannot be transferred
either between France and Italy regarding the quantities and unit costs of the
biopsies. CONCLUSIONS: Using CA and PCA enables health care professionals to
rapidly emphasize the variability of data and therefore to determine the transfer-
ability of cost evaluations across locations.
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OBJECTIVES: To investigate the knowledge, awareness and attitudes of cardiolo-
gists about the risk and benefits associated with medicines and medical devices
and equipment, and of how well they are regulated and communicated in Turkey.
METHODS:An on –line questionnaire has been developed which include questions
about the level of education and experience; perceptions of the risks and benefits
associated with medicines and medical devices; experiences of medicines and
medical devices; perceptions of and attitudes towards the regulation of medicines
and medical devices; attitudes towards the communication of information about
the risks and benefits associated with medicines and medical devices; usage of and
trust in communication of information about the risks and benefits associated with
medicines and medical devices. RESULTS: A total of 250 members of the Turkish
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